A phase II study of bevacizumab (B) and high-dose aldesleukin (IL-2) in patients (p) with metastatic renal cell carcinoma (mRCC): A Cytokine Working Group Study (CWGS).
暂无分享，去创建一个
Jeffrey W. Clark | M. Atkins | J. Sosman | M. Regan | M. Ernstoff | J. Dutcher | U. Vaishampayan | B. Curti | U. B. Dandamudi | M. Ghebremichael | U. Dandamudi